New hope for transplant patients: testing better first treatment for dangerous complication
NCT ID NCT06660355
Summary
This study aims to find the better first treatment for chronic graft-versus-host disease (cGVHD), a serious complication that can occur after a bone marrow transplant. Researchers will compare two drugs—ruxolitinib (already approved for later treatment) and prednisone (current standard)—in 120 adults who need their first systemic therapy for cGVHD. The goal is to see which drug more effectively controls the disease with fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
-
Univ of Miami - Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23219, United States
Contact
Conditions
Explore the condition pages connected to this study.